CompletedPhase 1

Comparison Between Topical Mitomycin C and Cyclosporine

Egypt57 participantsStarted 2021-01-01

Plain-language summary

Pterygium is a disease associated with proliferation of the fibrovascular tissues of the conjunctiva into the cornea and is related to factors such as ultraviolet light exposure, chronic stimulation, inflammation, climate, and genetics.

Who can participate

Age range45 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of primary pterygium * Pterygium size \> or equal 2mm (the horizontal length of the tissue from limbus to cornea will be measured by slit lamp biomicroscopy). * Ocular discomfort refractory to medical treatment. * Visual loss induced by pterygium. * Adult Egyptian population Exclusion Criteria: * Patients who had recurrent pterygium or allergy to topical Cyclosporine. * Patients who had allergy from Mitomycin C. * Pregnant women. * Patients with uncontrollable systemic diseases such as hypertension, diabetes, or cardiovascular diseases. * Patients with diseases of the eye surface such as conjunctivitis and keratitis. * Patients with a history of eye surgery within the previous six months.

What they're measuring

Post Operative recurrence of pterygium

Timeframe: from baseline to 3 months after primary pterygium surgery.

Trial details

NCT IDNCT05627947

SponsorEgymedicalpedia

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-06-15

View on ClinicalTrials.gov More Pterygium trials